| [1] |
Ronco C, Bellomo R, Kellum JA. Acute kidney injury [J]. Lancet, 2019, 394(10212): 1949-1964.
|
| [2] |
He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms [J]. Kidney Int, 2017, 92(5): 1071-1083.
|
| [3] |
Yeh TH, Tu KC, Wang HY, et al. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease [J]. Int J Mol Sci, 2024, 25(3): 1755.
|
| [4] |
Ouyang Q, Wang C, Sang T, et al. Depleting profibrotic macrophages using bioactivated in vivo assembly peptides ameliorates kidney fibrosis [J]. Cell Mol Immunol, 2024, 21(8): 826-841.
|
| [5] |
Qin W, Huang J, Zhang M, et al. Nanotechnology-based drug delivery systems for treating acute kidney injury [J]. ACS Biomater Sci Eng, 2024, 10(10): 6078-6096.
|
| [6] |
Kamaly N, He JC, Ausiello DA, et al. Nanomedicines for renal disease: current status and future applications [J]. Nat Rev Nephrol, 2016, 12(12): 738-753.
|
| [7] |
Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis [J]. Nat Rev Nephrol, 2019, 15(3): 144-158.
|
| [8] |
Yao W, Chen Y, Li Z, et al. Single cell RNA sequencing identifies a unique inflammatory macrophage subset as a druggable target for alleviating acute kidney injury [J]. Adv Sci (Weinh), 2022, 9(12): e2103675.
|
| [9] |
Conway BR, O′Sullivan ED, Cairns C, et al. Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease [J]. J Am Soc Nephrol, 2020, 31(12): 2833-2854.
|
| [10] |
Zhang YL, Tang TT, Wang B, et al. Identification of a novel ECM remodeling macrophage subset in AKI to CKD transition by integrative spatial and single-cell analysis [J]. Adv Sci (Weinh), 2024, 11(38): e2309752.
|
| [11] |
Wang YY, Jiang H, Pan J, et al. Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury [J]. J Am Soc Nephrol, 2017, 28(7): 2053-2067.
|
| [12] |
Luo L, Wang S, Hu Y, et al. Precisely regulating M2 subtype macrophages for renal fibrosis resolution [J]. ACS Nano, 2023, 17(22): 22508-22526.
|
| [13] |
Zimmerman KA, Bentley MR, Lever JM, et al. Single-cell RNA sequencing identifies candidate renal resident macrophage gene expression signatures across species [J]. J Am Soc Nephrol, 2019, 30(5): 767-781.
|
| [14] |
Yao W, Liu M, Li Z, et al. CD38hi macrophages promote fibrotic transition following acute kidney injury by modulating NAD＋ metabolism [J]. Mol Ther, 2025, 33(7): 3434-3452.
|
| [15] |
Cheung MD, Erman EN, Moore KH, et al. Resident macrophage subpopulations occupy distinct microenvironments in the kidney [J]. JCI Insight, 2022, 7(20): e161078.
|
| [16] |
Hu Z, Zhan J, Pei G, et al. Depletion of macrophages with clodronate liposomes partially attenuates renal fibrosis on AKI-CKD transition [J]. Ren Fail, 2023, 45(1): 2149412.
|
| [17] |
van Alem CMA, Boonstra M, Prins J, et al. Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat [J]. Nephrol Dial Transplant, 2018, 33(1): 44-53.
|
| [18] |
Shen Z, Wang X, Lu L, et al. Bilirubin- modified chondroitin sulfate-mediated multifunctional liposomes ameliorate acute kidney injury by inducing mitophagy and regulating macrophage polarization [J]. ACS Appl Mater Interfaces, 2024, 16(45): 62693-62709.
|
| [19] |
Yang T, Li C, Wang X, et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle [J]. Bioact Mater, 2020, 5(4): 1053-1061.
|
| [20] |
Zhang L, Gong H, Gong X, et al. Bioengineered platelet nanoplatform enables renal-targeted dexamethasone delivery for chronic nephritis therapy with dual anti-inflammatory/anti-fibrotic effects and minimized systemic toxicity [J]. Bioact Mater, 2025, 52: 213-227.
|
| [21] |
An HW, Mamuti M, Wang X, et al. Rationally designed modular drug delivery platform based on intracellular peptide self-assembly [J]. Exploration (Beijing), 2021, 1(2): 20210153.
|
| [22] |
Yang J, An HW, Wang H, et al. Self-assembled peptide drug delivery systems [J]. ACS Appl Bio Mater, 2021, 4(1): 24-46.
|
| [23] |
Tang TT, Wang B, Wu M, et al. Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI [J]. Sci Adv, 2020, 6(33): eaaz0748.
|
| [24] |
Tang TT, Lv LL, Wang B, et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis [J]. Theranostics, 2019, 9(16): 4740-4755.
|
| [25] |
Xu F, Fei Z, Dai H, et al. Mesenchymal stem cell-derived extracellular vesicles with high PD-L1 expression for autoimmune diseases treatment [J]. Adv Mater, 2022, 34(1): e2106265.
|
| [26] |
Kim SH, Kim CH, Lee CH, et al. Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury [J]. Biomaterials, 2025, 318: 123165.
|
| [27] |
Huang Y, Ning X, Ahrari S, et al. Physiological principles underlying the kidney targeting of renal nanomedicines [J]. Nat Rev Nephrol, 2024, 20(6): 354-370.
|
| [28] |
Deng X, Zeng T, Li J, et al. Kidney-targeted triptolide-encapsulated mesoscale nanoparticles for high-efficiency treatment of kidney injury [J]. Biomater Sci, 2019, 7(12): 5312-5323.
|
| [29] |
Williams RM, Shah J, Ng BD, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium [J]. Nano Lett, 2015, 15(4): 2358-2364.
|
| [30] |
He J, Cao Y, Zhu Q, et al. Renal macrophages monitor and remove particles from urine to prevent tubule obstruction [J]. Immunity, 2024, 57(1): 106-123.e7.
|
| [31] |
Wu Q, Wang J, Wang Y, et al. Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment [J]. Nano Res, 2022, 15(4): 3556-3568.
|
| [32] |
Adal Y, Pratt L, Comper WD. Transglomerular transport of DEAE dextran in the isolated perfused kidney [J]. Microcirculation, 1994, 1(3): 169-174.
|
| [33] |
Asgeirsson D, Venturoli D, Rippe B, et al. Increased glomerular permeability to negatively charged Ficoll relative to neutral Ficoll in rats [J]. Am J Physiol Renal Physiol, 2006, 291(5): F1083-F1089.
|
| [34] |
Xiao Q, Zoulikha M, Qiu M, et al. The effects of protein corona on in vivo fate of nanocarriers [J]. Adv Drug Deliv Rev, 2022, 186: 114356.
|